Inovio Announces First Patient Dosed in Trial to Determine PENNVAX®-GP’s Ability to Induce Remission of HIV Infection
14 août 2018 08h00 HE
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that the first participant has been dosed with PENNVAX®-GP in a randomized clinical...
Inovio Pharmaceuticals Reports 2018 Second Quarter Financial Results
07 août 2018 16h05 HE
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), a late-stage biotechnology company focused on the development and commercialization of DNA...
Inovio Partners with AIDS Malignancy Consortium to Advance Inovio’s HPV Therapy for High-Grade Anal Dysplasia in HIV-positive Patients
06 août 2018 08h00 HE
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has entered into a partnership with the AIDS Malignancy Consortium (AMC) to...
Inovio Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 7, 2018
24 juil. 2018 08h00 HE
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., July 24, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2018 second...
Inovio’s MERS Vaccine Generates High Levels of Antibodies and Induces Broad-based T Cell Responses in Phase 1 Study
27 juin 2018 08h00 HE
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., June 27, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced positive Phase 1 results of its collaborative vaccine study with INO-4700...
Inovio Announces Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron’s PD-1 Inhibitor
21 juin 2018 08h00 HE
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., June 21, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has dosed its first patient as part of its Phase 1/2 immuno-oncology trial...
Inovio CEO to Speak on Viral Epidemic Preparedness Panel at BIO International Convention
31 mai 2018 08h00 HE
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., May 31, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. J. Joseph Kim, President and CEO, will address Inovio’s ability to respond...
Inovio Boosts Leadership Focused on Partnership and Grant Funding By Appointing Two New VPs for Business Development and R&D
24 mai 2018 08h00 HE
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., May 24, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has bolstered its efforts to attract partnerships and collaborations and...
Inovio Opens Phase 2 Trial for VGX-3100 in Third Indication To Treat HPV – The No. 1 Sexually Transmitted Disease
21 mai 2018 08h00 HE
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., May 21, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has commenced a Phase 2 clinical trial to evaluate the efficacy of VGX-3100...
Inovio Pharmaceuticals Demonstrates PSA Stabilizing Effect of INO-5150 Immunotherapy in Phase 1b Study for Prostate Cancer
17 mai 2018 08h00 HE
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., May 17, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced a poster presentation of additional prostate cancer data (Abstract #229675) at the...